Popular Articles

LNA-Based HIF-1 Alpha Inhibitor Shows Early Signs Of Clinical Benefit
Santaris Pharma announced that the cancer drug EZN-2968 - an inhibitor of HIF-1alpha, jointly developed by Enzon Pharmaceuticals and Santaris Pharma A/S - was well tolerated and showed early signs of clinical benefit in previously treated cancer patients with advanced malignancies. EZN-2968 is being evaluated in patients with solid tumors and lymphoma. The study data, which was presented at the 2009 American Society of Clinical Oncology (ASCO) annual meeting in Florida last week, demonstrated that EZN-2968 is well tolerated, and that early signs of clinical benefit - prolonged stable disease - were observed in several patients.
buy viagra
Spectranetics Receives CE Mark Approval For ThromCat(R)XT
Spectranetics Corporation (Nasdaq:SPNC) reported that it has received the CE mark approval for its next-generation ThromCat® XT Thrombus Removal System, a single-use, disposable device indicated for mechanical removal of thrombus from native coronary arteries and infra-inguinal arteries. The launch of the product will commence immediately within the European Union. The approval triggers a milestone payment of $1.5 million pursuant to the Company"s Amended Development and Regulatory Services agreement with Kensey Nash Corporation (Nasdaq:KNSY).
News of the day
FDA Approves TYVASO (Treprostinil) Inhalation Solution For The Treatment Of Pulmonary Arterial Hypertension
United Therapeutics Corporation (Nasdaq: UTHR) announced that the United States Food and Drug Administration (FDA) has approved TYVASO (treprostinil) Inhalation Solution for the treatment of pulmonary arterial hypertension (PAH) using the TYVASO Inhalation System (which includes the Optineb-ir device and accessories). TYVASO is indicated to increase walk distance in patients with NYHA Class III symptoms associated with WHO Group I PAH, which includes multiple etiologies such as idiopathic and familial PAH as well as PAH associated with scleroderma and congenital heart disease.
Diagnostics

Grant From American Heart Association For Cardiac Myogenesis Research Center At UT Southwestern

UT Southwestern Medical Center researchers Drs. Jay Schneider, Joseph Hill and Eric Olson have been awarded a $2 million grant from the American Heart Association to study the development and mechanisms of generating new cardiac muscle cells. UT Southwestern was one of only three institutions in the country to receive the highly competitive award, which will establish an American Heart Association-Jon Holden DeHaan Foundation Cardiac Myogenesis Research Center. Each center will conduct a number of basic science research projects to learn more about how cardiac muscle cells develop and work together. The AHA grant provides funding through 2012. "Our grant submission involved a small-molecule drug that we discovered by screening the UT Southwestern chemical library with cardiac stem cells," said Dr. Schneider, assistant professor of internal medicine. "Original studies of that drug were done in cultured stem cells, but we have now shown that it actually works as a drug in the adult heart by targeting a rare population of native cardiac stem cells and by activating muscle genes in these cells." Dr. Hill, chief of cardiology, said the finding could lead to treatments that activate stem cells within the heart to emerge as functional muscle cells. "We are hopeful that opportunities presented to our researchers through the funding provided by this grant will lead to improved outcomes for heart attack and heart failure patients," he said. The UT Southwestern researchers said their investigations could significantly help advance the understanding of stem cells" role in heart disease and repair, leading to new ways to care for patients with heart attacks or congestive heart failure by stimulating heart cell regeneration. "The goal is to use small molecules and microRNAs (ribonucleic acids) as probes to understand the mechanistic barriers that prevent the human heart from repairing itself after injury," said Dr. Schneider. "By doing so, we hope to develop new therapeutics based on small molecules and microRNAs that will overcome these barriers and induce the human heart to regenerate after injury." Dr. Olson, chairman of molecular biology and director of the Nancy B. and Jake L. Hamon Center for Basic Research in Cancer and the Nearburg Family Center for Basic and Clinical Research in Pediatric Oncology, said the award will unite researchers from several fields to attack the problem. For instance, Dr. Schneider worked collaboratively with Dr. Steven McKnight, chairman of biochemistry at UT Southwestern, during the initial research for the grant proposal. "This grant from the AHA will enable us to translate basic discoveries in the laboratory into new therapeutic approaches for improving function of the failing heart. We intend to take an interdisciplinary approach and draw from the expertise of basic scientists and clinicians to achieve this goal," Dr. Olson said. His research focuses on genes that control development of the heart in embryos, and how those genes can help repair damaged adult hearts. Other Cardiac Myogenesis Research Centers receiving the grant are the University of Pennsylvania and the University of Minnesota. The Jon Holden DeHaan Foundation of Naples, Fla., has a long history of funding AHA cardiovascular research and cumulatively has contributed almost $5 million for this purpose. The American Heart Association-Jon Holden DeHaan Foundation Cardiac Myogenesis Research Center Program is the most ambitious partnership undertaken by the two organizations. Katherine Morales UT Southwestern Medical Center


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):